Bioceres Crop Solutions Corp. (BIOX)

NASDAQ: BIOX · USD

$0.24

-0.00 (-0.2%)· Recorded snapshot

Market cap	15M
Revenue (ttm)	237.8M
Net income (ttm)	-46.9M
EPS (ttm)	-$0.74
Shares out	63.5M
Volume	373,276
Beta	0.47

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 237.8M
Net income (ttm): -46.9M
EPS (ttm): -$0.74
Market cap: 15M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALB	Albemarle Corporation	11.4B	198.9x	1.9x	4.1%	+12.8%	+1.9%	Trzymaj
APD	Air Products and Chemicals, Inc.	68.3B	—	5.4x	8.9%	+5.2%	+23.1%	Trzymaj
AVY	Avery Dennison Corporation	13.7B	19.8x	1.5x	15.1%	+3.3%	+1.6%	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 9.3P50 13.2P75 19.6

Trailing P/En/a

P25 12.2P50 18.6P75 31.2

ROE-28.1

P25 -22.4P50 2.4P75 17.1

ROIC-0.2

P25 -9.7P50 4.4P75 13.2

Benchmarks · 1M

All BIOX indicators

Market & fundamental data

Available fields

221

Groups with data

Currency

USD

Showing 221 of 221 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001769484
Company name	Bioceres Crop Solutions Corp.
Country	Argentina
Country code	US
CUSIP number	G1117K114
Earnings date	2026-11-11
Earnings time	amc
Employees	751
Employees change	362
Employees growth	93.06%
Enterprise value	$239.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Founded	2001
Industry	Agricultural Inputs
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG1117K1141
Last 10-K release date	2025-11-10
Last earnings date	2026-09-14
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$15M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$0.24
Price currency	USD
Sector	Materials
SIC code	2870
Stock price date	2026-10-28
Symbol	BIOX
Website	https://investors.biocerescrops.com/home/default.aspx

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-311.15%
EV/EBITDA	15.01x
EV/FCF	3.01x
EV/Sales	1.01x
FCF / EV yield	33.18%
FCF yield	528.46%
Industry forward P/E	12.83x
Industry P/E	45.17x
P/(FCF - SBC) ratio	0.19x
P/(OCF - SBC) ratio	0.19x
P/B ratio	0.39x
P/FCF ratio	0.19x
P/OCF ratio	0.18x
P/S ratio	0.06x
Price/EBITDA ratio	0.94x
Sector forward P/E	15.04x
Sector P/E	22.59x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-0.21%
EBITDA margin	6.72%
FCF margin	28.74%
Gross margin	34.69%
Operating margin	-0.21%
Pretax margin	-19.76%
Profit margin	-19.72%
Profit per employee	$-62,450
Revenue per employee	$316,644
ROA	-0.05%
ROA (5Y)	2.51%
ROCE	-0.24%
ROE	-28.05%
ROE (5Y)	-7.8%
ROIC	-0.16%
ROIC (5Y)	2.38%
SBC / revenue	0.74%
Tax / revenue	1.43%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth 3Y	140.54%
Gross profit growth	-44.94%
Gross profit growth (Q)	-45.76%
Gross profit growth 3Y	-22.3%
Gross profit growth 5Y	0.5%
Net income growth quarters	1
Net income growth years	0
OCF growth	1,344.86%
OCF growth 3Y	93.85%
Revenue growth	-37.96%
Revenue growth (Q)	-23.35%
Revenue growth (QoQ)	49.21%
Revenue growth 3Y	-17%
Revenue growth 5Y	6.47%
Revenue growth quarters	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.4M
Depreciation and amortization	$16.5M
EBIT	$-500,000
EBITDA	$16M
EPS	$-0.74
FCF per share	$1.25
Financing cash flow	$-85.1M
Free cash flow	$79.5M
Free cash flow minus SBC	$77.5M
Gross profit	$82.5M
Income taxes	$3.4M
Investing cash flow	$-5.1M
Net borrowing	$-68.7M
Net cash flow	$-18.1M
Net income	$-46.9M
Operating cash flow minus SBC	$79.8M
Operating income	$-500,000
Revenue	$237.8M
Stock-based compensation	$2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.61
Debt / EBITDA	14.83
Debt / equity	3.69
Debt / FCF	2.98
Goodwill	$36.1M
Interest coverage	-0.01
Long-term assets	$256.1M
Long-term liabilities	$140.2M
Net cash (debt)	$-224.6M
Net cash / market cap	-1,492.91%
Net debt / EBITDA	14.07
Net debt / equity	3.5
Net debt / FCF	2.83
Piotroski F-Score	3
Property, plant and equipment	$71.7M
Shareholders' equity	$64.1M
Tangible book value	$-79.2M
Tangible book value per share	$-1.25
Total assets	$471.3M
Total cash	$12.2M
Total debt	$236.8M
Total liabilities	$407.2M
WACC	16.37%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.39
Current assets	$215.2M
Current liabilities	$267M
Current ratio	0.81
Inventory turnover	2.27
Net working capital	$104M
Quick ratio	0.46
Working capital	$-51.8M
Working capital turnover	-5.84

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.27%
Dividend yield	0%
Shareholder yield	-1.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$0.41
1D price change	-0.17%
1M price change	-33.93%
1M total return	-33.93%
1W price change	0.98%
1W total return	0.98%
1Y price change	-87.64%
1Y return CAGR	-87.65%
1Y total return	-87.64%
20-day SMA	$0.29
200-day SMA	$0.48
3M price change	-24.88%
3M total return	-24.87%
3Y price change	-97.74%
3Y return CAGR	-71.72%
3Y total return	-97.74%
50-day SMA	$0.36
50-day SMA vs 200-day SMA	50under200
52-week high	$2.10
52-week high date	2025-10-31
52-week low	$0.19
52-week low date	2026-10-23
5Y price change	-98.1%
5Y return CAGR	-54.73%
5Y total return	-98.1%
6M price change	-52.71%
6M total return	-52.71%
All-time high	$17.94
All-time high date	2021-03-16
All-time low	$0.19
All-time low date	2026-10-23
Average true range (ATR)	$0.04
Average volume	192.5K
Beta (1Y)	2.87
Beta (2Y)	1.36
Beta (5Y)	0.47
Change from 52-week high	-88.71%
Change from 52-week low	24.74%
Change from all-time high	-98.62%
Change from all-time low	30.16%
Change from open	3.04%
Day's gap	-3.12%
Dollar volume	$88,466
High price	$0.25
Low price	$0.22
Monthly RSI	24.33
Open price	$0.23
Position in 52-week range	61.22%
Premarket change	0%
Premarket close	$0.24
Premarket price	$0.24
Previous close	$0.24
Price vs 150-day SMA	-39.07%
Price vs 20-day SMA	-15.05%
Price vs 200-day SMA	-48.46%
Price vs 50-day SMA	-31.02%
Relative volume	1.96
RSI	35.41
Sharpe ratio	-1.66
Sharpe ratio (3Y)	-1.36
Sharpe ratio (5Y)	-0.93
Sortino ratio	-2.11
Sortino ratio (3Y)	-1.76
Sortino ratio (5Y)	-1.21
Volume	373.3K
Weekly RSI	29.17
YTD price change	-81.12%
YTD total return	-81.12%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	44.9M
Float percentage	70.77%
Shares change (QoQ)	0%
Shares change (YoY)	1.27%
Shares held by insiders	1.31%
Shares held by institutions	6.3%
Shares outstanding	63.5M
Short % of float	2.06%
Short % of shares	1.46%
Short ratio	1.8 days

Deeper analysis on BIOX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BIOX report

Is a complete BIOX research report available?

No complete published report is available for Bioceres Crop Solutions Corp. (BIOX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Bioceres Crop Solutions Corp. (BIOX)

Price

Financial snapshot

Fair-value bridge

Latest news · BIOX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BIOX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BIOX

Frequently asked questions